Foco cáncer de pulmón y oncologÃa gastrointestinal
Foco cáncer de pulmón y oncologÃa gastrointestinal
Foco cáncer de pulmón y oncologÃa gastrointestinal
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Bevacizumab extends survival beyond historical <br />
benchmark of 1 year <br />
Probability of OS <br />
1.0 <br />
0.9 <br />
0.8 <br />
0.7 <br />
0.6 <br />
0.5 <br />
0.4 <br />
0.3 <br />
0.2 <br />
E4599 overall pa@ent popula@on <br />
HR<br />
(95% CI)<br />
CP<br />
(n=444)<br />
Bevacizumab<br />
15mg/kg + CP<br />
(n=434)<br />
0.79<br />
(0.67–0.92)<br />
p value 0.003<br />
Median OS<br />
(months) 10.3 12.3<br />
0.1 <br />
10.3 12.3 <br />
0 <br />
0 6 12 18 24 30 36 42 <br />
Dura@on of survival (months) <br />
Sandler, et al. NEJM 2006
Change language